Cspc Innovation Subsidiary Gets FDA Clearance for Monkeypox mRNA Vaccine Trial

Stock News08-10 15:52

Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., received notification from the U.S. Food and Drug Administration (FDA) regarding the Investigational New Drug (IND) application for SYS6037 injection, a monkeypox mRNA vaccine.

The vaccine, developed in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences, has been approved by the FDA to proceed with clinical trials in the United States. Monkeypox is caused by the monkeypox virus, which belongs to the Orthopoxvirus genus of the Poxviridae family.

SYS6037 injection is a multi-antigen monkeypox vaccine encoded by a single mRNA strand, designed for the prevention of monkeypox. Its streamlined technical approach facilitates quality control during production, significantly reduces manufacturing costs, and enhances the vaccine's controllability and accessibility.

Preclinical studies indicate that compared to the live attenuated vaccine (Tiantan strain), SYS6037 injection demonstrates superior immunogenicity and protective efficacy. It also exhibits broad-spectrum cross-reactivity against multiple orthopoxvirus antigens, positioning it as a potentially competitive monkeypox vaccine product that will further diversify the company's mRNA vaccine innovation pipeline.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1186200098?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-10 15:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1186200098","market":"nz","top_or_hot":-1,"title":"Cspc Innovation Subsidiary Gets FDA Clearance for Monkeypox mRNA Vaccine Trial","media":"Stock News","content":"<p><b>Cspc Innovation Pharmaceutical Co.,Ltd.</b> (300765.SZ) announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., received notification from the U.S. Food and Drug Administration (FDA) regarding the Investigational New Drug (IND) application for SYS6037 injection, a monkeypox mRNA vaccine. <br><br>The vaccine, developed in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences, has been approved by the FDA to proceed with clinical trials in the United States. Monkeypox is caused by the monkeypox virus, which belongs to the Orthopoxvirus genus of the Poxviridae family. <br><br>SYS6037 injection is a multi-antigen monkeypox vaccine encoded by a single mRNA strand, designed for the prevention of monkeypox. Its streamlined technical approach facilitates quality control during production, significantly reduces manufacturing costs, and enhances the vaccine's controllability and accessibility. <br><br>Preclinical studies indicate that compared to the live attenuated vaccine (Tiantan strain), SYS6037 injection demonstrates superior immunogenicity and protective efficacy. It also exhibits broad-spectrum cross-reactivity against multiple orthopoxvirus antigens, positioning it as a potentially competitive monkeypox vaccine product that will further diversify the company's mRNA vaccine innovation pipeline.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cspc Innovation Subsidiary Gets FDA Clearance for Monkeypox mRNA Vaccine Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCspc Innovation Subsidiary Gets FDA Clearance for Monkeypox mRNA Vaccine Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-08-10 15:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><b>Cspc Innovation Pharmaceutical Co.,Ltd.</b> (300765.SZ) announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., received notification from the U.S. Food and Drug Administration (FDA) regarding the Investigational New Drug (IND) application for SYS6037 injection, a monkeypox mRNA vaccine. <br><br>The vaccine, developed in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences, has been approved by the FDA to proceed with clinical trials in the United States. Monkeypox is caused by the monkeypox virus, which belongs to the Orthopoxvirus genus of the Poxviridae family. <br><br>SYS6037 injection is a multi-antigen monkeypox vaccine encoded by a single mRNA strand, designed for the prevention of monkeypox. Its streamlined technical approach facilitates quality control during production, significantly reduces manufacturing costs, and enhances the vaccine's controllability and accessibility. <br><br>Preclinical studies indicate that compared to the live attenuated vaccine (Tiantan strain), SYS6037 injection demonstrates superior immunogenicity and protective efficacy. It also exhibits broad-spectrum cross-reactivity against multiple orthopoxvirus antigens, positioning it as a potentially competitive monkeypox vaccine product that will further diversify the company's mRNA vaccine innovation pipeline.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0226","symbol_name":"食品制造","start_time":0,"source_url":"","article_id":"1186200098","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1186200098","pubTimestamp":1786348339,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., received notification from the U.S. Food and Drug...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300765":"石药创新","BK0226":"食品制造","PSYK":"PSYK ETF","MRNY":"MRNA期权收益策略ETF-YieldMax","IBBQ":"Invesco Nasdaq Biotechnology ETF","IBBJ":"Defiance Nasdaq Junior Biotechnology ETF","BMED":"iShares Health Innovation Active ETF","MRNX":"Defiance Daily Target 2X Long MRNA ETF","MDTX":"Corgi MediaTek 2x Daily ETF"},"translate_title":"石药集团创新子公司获得FDA批准开展猴痘mRNA疫苗试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300765":1,"MDTX":1,"PSYK":1,"BMED":1,"IBBJ":1,"MRNX":1,"IBBQ":1,"MRNY":1},"content_text":"Cspc Innovation Pharmaceutical Co.,Ltd. (300765.SZ) announced that its controlling subsidiary, CSPC Megalith Biopharmaceutical Co., Ltd., received notification from the U.S. Food and Drug Administration (FDA) regarding the Investigational New Drug (IND) application for SYS6037 injection, a monkeypox mRNA vaccine. The vaccine, developed in collaboration with the Institute of Microbiology of the Chinese Academy of Sciences, has been approved by the FDA to proceed with clinical trials in the United States. Monkeypox is caused by the monkeypox virus, which belongs to the Orthopoxvirus genus of the Poxviridae family. SYS6037 injection is a multi-antigen monkeypox vaccine encoded by a single mRNA strand, designed for the prevention of monkeypox. Its streamlined technical approach facilitates quality control during production, significantly reduces manufacturing costs, and enhances the vaccine's controllability and accessibility. Preclinical studies indicate that compared to the live attenuated vaccine (Tiantan strain), SYS6037 injection demonstrates superior immunogenicity and protective efficacy. It also exhibits broad-spectrum cross-reactivity against multiple orthopoxvirus antigens, positioning it as a potentially competitive monkeypox vaccine product that will further diversify the company's mRNA vaccine innovation pipeline.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1186200098","isCrawlerRequest":true}